Media influence on Herceptin subsidization in Australia: Application of the rule of rescue?

Journal of the Royal Society of Medicine

Volumn 101, Issue 6, 2008, Pages 305-312

  MacKenzie, Ross ^a   Chapman, Simon ^a   Salkeld, Glenn ^a   Holding, Simon ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; AUSTRALIA; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; FAMILY; GOVERNMENT; HAIR LOSS; HEALTH CARE ACCESS; HEALTH CARE FINANCING; HEALTH CARE POLICY; HUMAN; NAUSEA; RISK REDUCTION; TELEVISION; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; ECONOMICS; FEMALE; MASS MEDIUM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUSTRALIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GOVERNMENT PROGRAMS; HEALTH POLICY; HUMANS; MASS MEDIA;

EID: 47749109917     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.2008.070289     Document Type: Article

References (94)

1. Tony Abbott, Minister for Health and Ageing. Herceptin Media Release, 22/08/2006. ABB120/06
2. Department of Health and Ageing, Australia. PBAC Outcomes http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ health-pbs-general-outcomes.htm (accessed 3/12/2007)
3. Chandler J. Counting the cost of powerful new cancer drugs. The Age 12/08/2005
4. Department of Health and Ageing, Australia Listing of Herceptin on the PBS Fact Sheet. 22/08/2006
5. The Cancer Council Australia. Peak cancer groups call for rapid PBS listing of life saving drug Media release. 20/10/2006. http://www.cancer. org.au/documents/20OCT05_TCCA_COSA_Herceptin_listing.pdf (accessed 13/03/2007)
6. Breast Cancer Campaign Australia. Campaign for Herceptin funding - for the treatment of early breast cancer. 2007 http://www.bcna.org.au/cms/ details.asp?NewsID=556 (accessed 15/03/2007)
7. Breast Cancer Network Australia. Herceptin campaign. 2007 http://www.bcna.org.au/index.php?option=com_content&task=view&id= 419&Itemid=595
8. Department of Health and Ageing, Australia. Pharmaceutical Benefits Schedule. Trastuzumab. 2007 http://www.pbs.gov.au/html/consumer/search/ results?medicine=herceptin&form-type=simple (accessed 4/03/2007)
9. Murray S. Trastuzumab (Herceptin) and HER2-positive breast cancer. CMAJ 2006;174:36-7
10. Barrett A, Roques T, Small M, Smith RD. Rationing. How much will Herceptin really cost? BMJ 2006;333:1118-20
11. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. 28th San Antonio Breast Cancer Symposium 8-11 Dec 2005; San Antonio, Texas, USA.:1 (abstract)
12. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEJM 2005;353:1673-84
13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM 2005;353:1659-72
14. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. NEJM 2006;354:809-20
15. Smith I, Proctor M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36
16. Herceptin and early breast cancer: a moment for caution. Editorial. Lancet 2005;366:1673
17. Roche. Media News. In: Herceptin approved in Europe for early use in HER2-positive breast cancer 24/05/2006. http://www.roche.com/med-cor-2006- 05-24 (accessed 19/03/2007)
18. Kondro W, Sibbald B. Patient demand and politics push Herceptin forward. CMAJ 2005;173:347-8
19. Booth CM, Dranitsaris G, Gainford MC, et al. External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer. BMC Cancer 2007;7:110
20. Ferner RE, McDowell SE. How NICE may be outflanked. BMJ 2006;332:1268-71
21. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005;16:909-14
22. Kurian AW, Thompson RN, Gaw AF, et al. A cost-effectiveness analysis of adjuvant Trastuzumab regimens in early HER2/neu-Positive breast cancer. J Clin Oncol 2007;25:634-41
23. Librato NL, Macchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007;25:625-33
24. Millar JA, Millward MJ. Cost effectiveness of Trastuzumab in the adjuvant treatment of early breast cancer: A lifetime model. Pharmacoeconomics 2007;25:429-42
25. Hillner BE, Smith TJ. Do the large benefits justify the large costs of adjuvant breast cancer Trastuzumab? J Clin Oncol 2007;25:611-3
26. Neyt M, Albrecht J, Cocquyt V. An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol 2006;17:381-90
27. Dent R, Clemons M. Adjuvant trastuzumab for breast cancer. BMJ 2005;331:1035-6
28. Moynihan R, Bero L, Ross-Degnan D, et al. Coverage by the news media of the benefits and risks of medications. NEJM 2000;342: 1645-50
29. Benelli E. The role of the media in steering public opinion on healthcare issues. Health Policy 2003;63:179-86
30. Brodie M, Hamel E, Altman D, et al. Health news and the American public, 1996-2002. J Health Polit Polic 2003;28:927-50
31. Grilli R, Ramsay C, Minozzi S. Mass media interventions: effects on health services utilisation. Cochrane Database of Systematic Reviews 2002; http://www.cochrane.org/reviews/en/ab000389.html (accessed 12/07/2007)
32. MacKenzie R, Chapman S, Holding S, McGeechan K. 'A matter of faith, not science': discourse on prostate cancer screening in Australian news media 2003-2006. J Roy Soc Med 2007;100:513-21
33. Clarke J. A comparison of breast, testicular and prostate cancer in mass print media (1996-2001). Soc Sci Med 2004;59:541-51
34. Clarke JEM. Cancer in the mass print media: fear uncertainty and the medical model. Soc Sci Med 2006;62:2591-600
35. Ooi E, Chapman S. An analysis of newspaper reports of cancer breakthroughs: hope or hype? Med J Aust 2003;179:639-43
36. Donelle L, Hoffman-Goetz L, Clarke JN. Ethnicity, genetics, and breast cancer: media portrayal of disease identities. Ethn Health 2005;10:185-97
37. Jones SC. Coverage of breast cancer in the Australian print media - does advertising and editorial coverage reflect correct social marketing messages? J Health Commun 2004;9:309-25
38. Jonsen AR. Bentham in a box: Technology assessment and health care allocation. Law Med Health Care 1986;14:172-4
39. McKie J, Richardson J. The rule of rescue. Soc Sci Med 2003;56:2407-19
40. Chapman S, MacKenzie R. The Australian Health News Research Collaboration. Med J Aust 2007;186:326
41. Entman RM. Framing: toward clarification of a fractured paradigm. J Communication 1993;43:51-8
42. Potter JW. Theory of Media Literacy: A Cognitive Approach. Thousand Oaks: Sage; 2004
43. Wallack L, Dorfman L, Jernigan D, et al. Media advocacy and public health: Power for prevention. Newbury Park: Sage; 1993
44. Nelkin D. Selling science: how the press covers science and technology. 2nd ed. New York: WH Freeman; 1995
45. Channel Seven. Seven Evening News Broadcast 22/08/2006
46. Nine Network. A Current Affair Broadcast 20/10/2005
47. Channel Seven. Seven Evening News Broadcast 20/10/2005
48. Channel Seven. Sunrise. Herceptin Broadcast 21/10/2005
49. Nine Network. National Nine Evening News 20/10/2005
50. Nine Network. Nightline Broadcast 20/10/2005
51. Channel Ten. Ten Late News Broadcast 20/10/2005
52. Channel Ten. Ten Late News Broadcast 2/02/2006
53. Nine Network. A Current Affair Broadcast 11/10/2005
54. Channel Seven. Today Tonight. Herceptin Broadcast 31/01/2006
55. Nine Network. A Current Affair Broadcast 31/01/2006
56. Nine Network. Today Broadcast 3/02/2006
57. SBS. World News Australia Broadcast 20/10/2005
58. Nine Network. National Nine Evening News Broadcast 1/10/2006
59. Nine Network. Nightline Broadcast 31/01/2006
60. SBS. World News Australia Late Broadcast 20/10/2005
61. Channel Ten. Ten Evening News Broadcast 20/10/2005
62. Montori V, Devereaux PJ, Adhikari NKJ, et al. Randomized trials stopped early for benefit. JAMA 2005;294:2203-9
63. Roche. Annual Report 2006 Business Report. http://www.roche.com/ gb06e.pdf (accessed 14/03/2007)
64. Channel Ten. Ten Late News Broadcast 17/07/2006
65. Channel Ten. Ten Evening News Broadcast 22/08/2005
66. Nine Network. Nightline Broadcast 22/08/2006
67. ABC. ABC News Broadcast 22/08/2006
68. Channel Seven. Seven Evening News Broadcast 17/05/2005
69. ABC. 7:30 Report Broadcast 13/03/2006
70. Channel Seven. Sunrise Broadcast 23/08/2006
71. Jonsen AR. Bentham in a box: Technology assessment and the artificial heart. West J Med 1986;145:685-6
72. Jenni KE, Lowenstein G. Explaining the 'Identifiable Victim Effect'. J Risk Uncertain 1997;14:235-57
73. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? Q J Med 2005;98:829-36
74. Clarke J, Amato D, Deber RB. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario. Can Med Assoc J 2001;165:595
75. Department of Health and Ageing Australia. PBAC Outcomes and Public Summary Documents. Carmustine, implant, 7.7 mg, Gliadel®. 2006 March http://www.health.gov.au/internet/wcms/publishing.nsf/content/ pbac-psd-carmustine-mar06 (accessed 2/05/2007)
76. Department of Health and Ageing Australia. PBAC Outcomes and Public Summary Documents. Imatinib Mesylate. 2003 http://www.health.gov.au/ internet/wcms/publishing.nsf/content/health-pbs-general-listing-pbacrec-sep03- positive-imati2.htm (accessed 2/05/2007)
77. Department of Health and Ageing Australia. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) Section F: Options to present additional relevant information. Guidance on the 'rule of rescue'. 2007 http://www.health.gov.au/internet/wcms/publishing.nsf/content/ pbacguidelines-index~pbacguidelines-part2~pbacguidelines-part2_f (accessed 24/04/2007)
78. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002;324:886-90
79. Smith I, Proctor M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36
80. Hind D, Pilgrim H, Ward S. Questions over adjuvant trastuzumab still remain. Lancet 2007;369:3-4
81. Potter J, Wetherell M, Chitty A. Quantification rhetoric-cancer on television. Discourse Soc 1991;2:333-65
82. Fryback DG, Craig BM. Measuring economic outcomes of cancer. J Natl Cancer Inst Monogr 2004;33:134-41
83. Brinsmead G, Williams A. Priority setting in health care: Matching decision criteria with policy objectives. In: Freemantle N, Hill S, (eds)Freemantle N, Hill S, (eds)Freemantle N, Hill S, (eds) Evaluating Pharmaceuticals for Health Policy and Reimbursement. Melbourne: Blackwell; 2004
84. Goodin R. Utilitarianism as a public philosophy. Cambridge: Cambridge University Press; 1995
85. Hadorn DC. Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue. JAMA 1991;265:2218-25
86. Henry DA, Birkett DJ. Changes to the Pharmaceutical Benefits Advisory Committee. Med J Aust 2001;174:209-10
87. Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine Press; 2006
88. Zinn C. Fury as Australia appoints former industry lobbyist to drugs watchdog. BMJ 2001;322:383
89. Loff B, Cordner S. Australian pharmaceutical committee set for a controversial restructure. Lancet 2000;356:1993
90. Lu CY, Williams K, Day R, et al. Access to high cost drugs in Australia. BMJ 2004;329:415-6
91. Hall WD, Ward R, Liauw WS, et al. Tailoring access to high cost, genetically targeted drugs. Med J Aust 2005;182:607-8
92. Department of Health and Ageing Australia. PBS Expenditure and prescriptions twelve months to 30 June 2006 http://www.health.gov.au/ internet/wcms/publishing.nsf/Content/A58720844CBFCB47CA257218000D91C7/ $File/complete.pdf (accessed 26/04/2007)
93. Wonder M, De Abreu Lourenco R. Factors considered in Pharmaceutical reimbursement in Australia: A role for the rule of rescue? Poster No. PHP8 ISPOR Asia Pacific, Kobe, Japan, 1-3 September 2003
94. Burton B, Rowell A. Unhealthy spin. BMJ 2003;326:1205-7